OR WAIT null SECS
December 19, 2022
The launch of Discovery Life Sciences’ new Proteomic Services Division offers a single source for large-scale population studies, biobank characterization, and multi-omic biomarker analysis.
GSK and Wave Life Sciences have entered into a collaboration to drive drug discovery and development for novel genetic targets.
AbCellera and Rallybio are teaming up to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.
December 16, 2022
Catalent is set to expand its biologics analytical services with its new facility in Durham, NC.
December 14, 2022
Emmes’ new facility is designed to support clients conducting cell and gene therapy research worldwide.
Under the collaboration between Vertex and Entrada, the companies will work on discovering and developing intracellular endosomal escape vehicle therapeutics for myotonic dystrophy type 1.
Thermo Fisher Scientific’s new facility in Hangzhou, China, is designed to boost biologics and sterile development and manufacturing capabilities in the Asia-Pacific region.
The objectives of the new opportunity are to improve the quality and/or use of RWD, promote better understanding of RWE study designs, and develop specific tools to evaluate aspects of RWE generation.
December 13, 2022
Amgen’s $27.8 billion acquisition of Horizon Therapeutics, an Irish biotechnology company, is one of the largest of 2022.
Takeda will purchase the rights to Nimbus Pharmaceuticals candidate, NDI-034858, which is currently being evaluated for treating multiple autoimmune diseases.